[Skip to Content]
[Skip to Content Landing]

Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active SurveillanceThe ERASE Randomized Clinical Trial

Educational Objective
To learn the effects of exercise on biochemical progression in men with localized prostate cancer under active surveillance.
1 Credit CME
Key Points

Question  Does a high-intensity interval training program improve cardiorespiratory fitness and delay the biochemical progression of prostate cancer in patients who are undergoing active surveillance?

Findings  In this randomized clinical trial of 52 male participants with prostate cancer under active surveillance, 12 weeks of high-intensity interval training significantly improved peak oxygen consumption, decreased prostate-specific antigen levels, and decreased prostate-specific antigen velocity compared with usual care. It also inhibited the growth of prostate cancer cell line LNCaP in this patient population.

Meaning  The findings of this study indicate that exercise may be an effective intervention for improving cardiorespiratory fitness and suppressing the progression of prostate cancer for patients undergoing active surveillance.


Importance  Men with prostate cancer who are undergoing active surveillance are at an increased risk of cardiovascular death and disease progression. Exercise has been shown to improve cardiorespiratory fitness, physical functioning, body composition, fatigue, and quality of life during and after treatment; however, to date only 1 exercise study has been conducted in this clinical setting.

Objective  To examine the effects of exercise on cardiorespiratory fitness and biochemical progression in men with prostate cancer who were undergoing active surveillance.

Design, Setting, and Participants  The Exercise During Active Surveillance for Prostate Cancer (ERASE) trial was a single-center, 2-group, phase 2 randomized clinical trial conducted at the University of Alberta, Edmonton, Canada. Eligible patients were recruited from July 24, 2018, to February 5, 2020. Participants were adult men who were diagnosed with localized very low risk to favorable intermediate risk prostate cancer and undergoing active surveillance. They were randomized to either the high-intensity interval training (HIIT) group or usual care group. All statistical analyses were based on the intention-to-treat principle.

Interventions  The HIIT group was asked to complete 12 weeks of thrice-weekly, supervised aerobic sessions on a treadmill at 85% to 95% of peak oxygen consumption (V̇o2). The usual care group maintained their normal exercise levels.

Main Outcomes and Measures  The primary outcome was peak V̇o2, which was assessed as the highest value of oxygen uptake during a graded exercise test using a modified Bruce protocol. Secondary and exploratory outcomes were indicators of biochemical progression of prostate cancer, including prostate-specific antigen (PSA) level and PSA kinetics, and growth of prostate cancer cell line LNCaP.

Results  A total of 52 male patients, with a mean (SD) age of 63.4 (7.1) years, were randomized to either the HIIT (n = 26) or usual care (n = 26) groups. Overall, 46 of 52 participants (88%) completed the postintervention peak V̇o2 assessment, and 49 of 52 participants (94%) provided blood samples. Adherence to HIIT was 96%. The primary outcome of peak V̇o2 increased by 0.9 mL/kg/min in the HIIT group and decreased by 0.5 mL/kg/min in the usual care group (adjusted between-group mean difference (1.6 mL/kg/min; 95% CI, 0.3-2.9; P = .01). Compared with the usual care group, the HIIT group experienced decreased PSA level (−1.1 μg/L; 95% CI, −2.1 to 0.0; P = .04), PSA velocity (−1.3 μg /L/y; 95% CI, −2.5 to −0.1; P = .04), and LNCaP cell growth (−0.13 optical density unit; 95% CI, −0.25 to −0.02; P = .02). No statistically significant differences were found in PSA doubling time or testosterone.

Conclusions and Relevance  The ERASE trial demonstrated that HIIT increased cardiorespiratory fitness levels and decreased PSA levels, PSA velocity, and prostate cancer cell growth in men with localized prostate cancer who were under active surveillance. Larger trials are warranted to determine whether such improvement translates to better longer-term clinical outcomes in this setting.

Trial Registration  ClinicalTrials.gov Identifier: NCT03203460

Sign in to take quiz and track your certificates

Buy This Activity
Our websites may be periodically unavailable between 12:00am CT March 25, 2023 and 4:00pm CT March 26, 2023 for regularly scheduled maintenance.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: May 20, 2021.

Published Online: August 19, 2021. doi:10.1001/jamaoncol.2021.3067

Corresponding Author: Kerry S. Courneya, PhD, Faculty of Kinesiology, Sport, and Recreation, University of Alberta, 1-113 University Hall, Edmonton, Alberta T6G 2H9, Canada (kerry.courneya@ualberta.ca).

Author Contributions: Dr Kang and Prof Courneya had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Kang, Fairey, Boulé, Courneya.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Kang.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Kang, Fairey, Boulé, Courneya.

Obtained funding: Kang, Courneya.

Administrative, technical, or material support: Kang, Fairey, Wharton, Courneya.

Supervision: Kang, Fairey, Boulé, Field, Courneya.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by grant 389507 from the Canadian Institutes of Health Research and grant D2017-1820 from Prostate Cancer Canada. Prof Courneya was supported by the Canada Research Chairs Program. Dr Kang was supported by the Alberta Innovates Graduate Studentship. Exercise equipment was donated by Apple Fitness, Edmonton, Alberta, Canada.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

Additional Contributions: We acknowledge the support of the following individuals: Niels-Erik Jacobsen, MD, Michael Chetner, MD, Sarah Rayner, RN, and Nupur Agarwal, CCPA, Northern Alberta Urology Center, assisted with patient recruitment; Sue Goruk, PhD, and Dhruvesh Patel, BSc, University of Alberta, assisted with blood assays; and Andria Morielli, PhD, Terri Wood, BSc, Ki-Yong An, PhD, Fernanda Arthuso, MSc, Stephanie Ntoukas, BSc, Spencer Allen, BSc, and Morgan Corbett, BSc, University of Alberta, assisted with exercise testing and intervention. These individuals received no additional compensation, outside of their usual salary, for their contributions. We also thank the study participants for their time and commitment.

Mahal  BA , Butler  S , Franco  I ,  et al.  Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015.   JAMA. 2019;321(7):704-706. doi:10.1001/jama.2018.19941 PubMedGoogle ScholarCrossref
Hamdy  FC , Donovan  JL , Lane  JA ,  et al; ProtecT Study Group.  10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer.   N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220 PubMedGoogle ScholarCrossref
Neal  DE , Metcalfe  C , Donovan  JL ,  et al; ProtecT Study Group.  Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received.   Eur Urol. 2020;77(3):320-330. doi:10.1016/j.eururo.2019.10.030 PubMedGoogle ScholarCrossref
Dragomir  A , Cury  FL , Aprikian  AG .  Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.   CMAJ Open. 2014;2(2):E60-E68. doi:10.9778/cmajo.20130037 PubMedGoogle ScholarCrossref
Keegan  KA , Dall’Era  MA , Durbin-Johnson  B , Evans  CP .  Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.   Cancer. 2012;118(14):3512-3518. doi:10.1002/cncr.26688 PubMedGoogle ScholarCrossref
Bourke  L , Smith  D , Steed  L ,  et al.  Exercise for men with prostate cancer: a systematic review and meta-analysis.   Eur Urol. 2016;69(4):693-703. doi:10.1016/j.eururo.2015.10.047 PubMedGoogle ScholarCrossref
Jones  LW , Antonelli  J , Masko  EM ,  et al.  Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer.   J Appl Physiol (1985). 2012;113(2):263-272. doi:10.1152/japplphysiol.01575.2011PubMedGoogle ScholarCrossref
Rundqvist  H , Augsten  M , Strömberg  A ,  et al.  Effect of acute exercise on prostate cancer cell growth.   PLoS One. 2013;8(7):e67579. doi:10.1371/journal.pone.0067579 PubMedGoogle Scholar
Hvid  T , Lindegaard  B , Winding  K ,  et al.  Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients.   Cancer Causes Control. 2016;27(2):165-174. doi:10.1007/s10552-015-0694-1 PubMedGoogle ScholarCrossref
Singh  F , Newton  RU , Baker  MK ,  et al.  Feasibility of presurgical exercise in men with prostate cancer undergoing prostatectomy.   Integr Cancer Ther. 2017;16(3):290-299. doi:10.1177/1534735416666373 PubMedGoogle ScholarCrossref
Demark-Wahnefried  W , Rais-Bahrami  S , Desmond  RA ,  et al.  Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.   Br J Cancer. 2017;117(9):1303-1313. doi:10.1038/bjc.2017.303 PubMedGoogle ScholarCrossref
Bourke  L , Stevenson  R , Turner  R ,  et al.  Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study.   Sci Rep. 2018;8(1):8374. doi:10.1038/s41598-018-26682-0 PubMedGoogle ScholarCrossref
Kang  DW , Fairey  AS , Boulé  NG , Field  CJ , Courneya  KS .  Exercise during active surveillance for prostate cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial.   BMJ Open. 2019;9(7):e026438. doi:10.1136/bmjopen-2018-026438 PubMedGoogle Scholar
Kodama  S , Saito  K , Tanaka  S ,  et al.  Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis.   JAMA. 2009;301(19):2024-2035. doi:10.1001/jama.2009.681 PubMedGoogle ScholarCrossref
McInnis  KJ , Balady  GJ .  Comparison of submaximal exercise responses using the Bruce vs modified Bruce protocols.   Med Sci Sports Exerc. 1994;26(1):103-107. doi:10.1249/00005768-199401000-00017 PubMedGoogle ScholarCrossref
Beltz  NM , Gibson  AL , Janot  JM , Kravitz  L , Mermier  CM , Dalleck  LC .  Graded exercise testing protocols for the determination of VO2max: historical perspectives, progress, and future considerations.   J Sports Med (Hindawi Publ Corp). 2016;2016:3968393. doi:10.1155/2016/3968393 PubMedGoogle Scholar
Arlen  PM , Bianco  F , Dahut  WL ,  et al; Prostate Specific Antigen Working Group.  Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.   J Urol. 2008;179(6):2181-2185. doi:10.1016/j.juro.2008.01.099 PubMedGoogle ScholarCrossref
Rikli  RE , Jones  CJ .  Senior Fitness Test Manual. Human Kinetics; 2013.
American College of Sports Medicine.  ACSM's Guidelines for Exercise Testing and Prescription. Lippincott Williams & Wilkins; 2013.
Godin  G , Shephard  RJ .  A simple method to assess exercise behavior in the community.   Can J Appl Sport Sci. 1985;10(3):141-146.PubMedGoogle Scholar
Borm  GF , Fransen  J , Lemmens  WA .  A simple sample size formula for analysis of covariance in randomized clinical trials.   J Clin Epidemiol. 2007;60(12):1234-1238. doi:10.1016/j.jclinepi.2007.02.006 PubMedGoogle ScholarCrossref
Loprinzi  PD , Kohli  M .  Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006.   Mayo Clin Proc. 2013;88(1):11-21. doi:10.1016/j.mayocp.2012.10.012 PubMedGoogle ScholarCrossref
Burton  AJ , Martin  RM , Donovan  JL ,  et al.  Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.   Cancer Epidemiol Biomarkers Prev. 2012;21(10):1877-1885. doi:10.1158/1055-9965.EPI-12-0411 PubMedGoogle ScholarCrossref
Stofan  JR , DiPietro  L , Davis  D , Kohl  HW  III , Blair  SN .  Physical activity patterns associated with cardiorespiratory fitness and reduced mortality: the Aerobics Center Longitudinal Study.   Am J Public Health. 1998;88(12):1807-1813. doi:10.2105/AJPH.88.12.1807 PubMedGoogle ScholarCrossref
Scott  JM , Zabor  EC , Schwitzer  E ,  et al.  Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis.   J Clin Oncol. 2018;36(22):2297-2305. doi:10.1200/JCO.2017.77.5809 PubMedGoogle ScholarCrossref
Cormie  P , Galvão  DA , Spry  N ,  et al.  Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.   BJU Int. 2015;115(2):256-266. doi:10.1111/bju.12646 PubMedGoogle ScholarCrossref
Galvão  DA , Spry  N , Denham  J ,  et al.  A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR.   Eur Urol. 2014;65(5):856-864. doi:10.1016/j.eururo.2013.09.041 PubMedGoogle ScholarCrossref
Galvão  DA , Taaffe  DR , Spry  N , Joseph  D , Newton  RU .  Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.   J Clin Oncol. 2010;28(2):340-347. doi:10.1200/JCO.2009.23.2488 PubMedGoogle ScholarCrossref
Segal  RJ , Reid  RD , Courneya  KS ,  et al.  Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer.   J Clin Oncol. 2009;27(3):344-351. doi:10.1200/JCO.2007.15.4963 PubMedGoogle ScholarCrossref
Segal  RJ , Reid  RD , Courneya  KS ,  et al.  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.   J Clin Oncol. 2003;21(9):1653-1659. doi:10.1200/JCO.2003.09.534 PubMedGoogle ScholarCrossref
Culos-Reed  SN , Robinson  JW , Lau  H ,  et al.  Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention.   Support Care Cancer. 2010;18(5):591-599. doi:10.1007/s00520-009-0694-3 PubMedGoogle ScholarCrossref
Wall  BA , Galvão  DA , Fatehee  N ,  et al.  Exercise improves VO2max and body composition in androgen deprivation therapy-treated prostate cancer patients.   Med Sci Sports Exerc. 2017;49(8):1503-1510. doi:10.1249/MSS.0000000000001277 PubMedGoogle ScholarCrossref
Hojman  P , Gehl  J , Christensen  JF , Pedersen  BK .  Molecular mechanisms linking exercise to cancer prevention and treatment.   Cell Metab. 2018;27(1):10-21. doi:10.1016/j.cmet.2017.09.015 PubMedGoogle ScholarCrossref
Pedersen  L , Idorn  M , Olofsson  GH ,  et al.  Voluntary running suppresses tumor growth through epinephrine- and IL-6–dependent NK cell mobilization and redistribution.   Cell Metab. 2016;23(3):554-562. doi:10.1016/j.cmet.2016.01.011 PubMedGoogle ScholarCrossref
Carter  HB , Ferrucci  L , Kettermann  A ,  et al.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.   J Natl Cancer Inst. 2006;98(21):1521-1527. doi:10.1093/jnci/djj410 PubMedGoogle ScholarCrossref
Loeb  S , Carter  HB , Schaeffer  EM , Kettermann  A , Ferrucci  L , Metter  EJ .  Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.   Urology. 2011;77(1):143-147. doi:10.1016/j.urology.2010.04.068 PubMedGoogle ScholarCrossref
Dall’Era  MA , Konety  BR , Cowan  JE ,  et al.  Active surveillance for the management of prostate cancer in a contemporary cohort.   Cancer. 2008;112(12):2664-2670. doi:10.1002/cncr.23502 PubMedGoogle ScholarCrossref
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate cancer. Version 2.2021. Accessed February 17, 2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459
Vickers  AJ , Brewster  SF .  PSA velocity and doubling time in diagnosis and prognosis of prostate cancer.   Br J Med Surg Urol. 2012;5(4):162-168. doi:10.1016/j.bjmsu.2011.08.006 PubMedGoogle ScholarCrossref
Ngo  TH , Barnard  RJ , Tymchuk  CN , Cohen  P , Aronson  WJ .  Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States).   Cancer Causes Control. 2002;13(10):929-935. doi:10.1023/A:1021911517010 PubMedGoogle ScholarCrossref
Ornish  D , Weidner  G , Fair  WR ,  et al.  Intensive lifestyle changes may affect the progression of prostate cancer.   J Urol. 2005;174(3):1065-1069. doi:10.1097/01.ju.0000169487.49018.73 PubMedGoogle ScholarCrossref
Idorn  M , Hojman  P .  Exercise-dependent regulation of NK cells in cancer protection.   Trends Mol Med. 2016;22(7):565-577. doi:10.1016/j.molmed.2016.05.007 PubMedGoogle ScholarCrossref
Biro  PA , Thomas  F , Ujvari  B , Beckmann  C .  Can energetic capacity help explain why physical activity reduces cancer risk?   Trends Cancer. 2020;6(10):829-837. doi:10.1016/j.trecan.2020.06.001 PubMedGoogle ScholarCrossref
Hayes  BD , Brady  L , Pollak  M , Finn  SP .  Exercise and prostate cancer: evidence and proposed mechanisms for disease modification.   Cancer Epidemiol Biomarkers Prev. 2016;25(9):1281-1288. doi:10.1158/1055-9965.EPI-16-0223 PubMedGoogle ScholarCrossref
McCullough  DJ , Nguyen  LM-D , Siemann  DW , Behnke  BJ .  Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.   J Appl Physiol (1985). 2013;115(12):1846-1854. doi:10.1152/japplphysiol.00949.2013PubMedGoogle ScholarCrossref
Lee  K , Zhou  J , Norris  MK , Chow  C , Dieli-Conwright  CM .  Prehabilitative exercise for the enhancement of physical, psychosocial, and biological outcomes among patients diagnosed with cancer.   Curr Oncol Rep. 2020;22(7):71. doi:10.1007/s11912-020-00932-9 PubMedGoogle ScholarCrossref
Neal  D , Lilja  H .  Circulating tumor cell count as an indicator of treatment benefit in advanced prostate cancer.   Eur Urol. 2016;70(6):993-994. doi:10.1016/j.eururo.2016.06.014 PubMedGoogle ScholarCrossref
Galvão  DA , Hayne  D , Frydenberg  M ,  et al.  Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial.   BMJ Open. 2018;8(4):e022331. doi:10.1136/bmjopen-2018-022331 PubMedGoogle Scholar
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience

Lookup An Activity


My Saved Searches

You currently have no searches saved.


My Saved Courses

You currently have no courses saved.